SS
APTO

Steve Schonfeld’s Aptose Biosciences, Inc. APTO Stock Holding History

Steve Schonfeld’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-1,429
Closed -$3.65M – 1628
2019
Q4 		$3.65M Buy
+1,429
New +$1.86M 0.09% 249

Other funds holding APTO

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
DS
DRW Securities Chicago, Illinois $4.11B AUM 21.98% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
CA
Corriente Advisors Fort Worth, Texas $9.53M AUM 805.26% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
PM
Precept Management Dallas, Texas $126M AUM 36.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Steve Schonfeld's APTO Position: Q1 2020 in Review

Steve Schonfeld sold out of Aptose Biosciences, Inc. (APTO) in Q1 2020, closing a stake of 1,429 shares — an estimated $3.65M sold.

Steve Schonfeld first reported a position in APTO in Q4 2019 and held it in 1 quarter. The position peaked at $3.65M in Q4 2019. 51 funds tracked by Wall St. Rank hold APTO as of Q1 2020.

  • Steve Schonfeld reported no remaining Aptose Biosciences, Inc. position as of Q1 2020 after selling out during the quarter.
  • Steve Schonfeld sold 1,429 Aptose Biosciences, Inc. shares in Q1 2020, an estimated $3.65M.
  • Steve Schonfeld first reported a position in Aptose Biosciences, Inc. in Q4 2019 and held it in 1 quarter.
  • Steve Schonfeld's Aptose Biosciences, Inc. position peaked at $3.65M in Q4 2019.
  • 51 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q1 2020.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2020, filed 15 May 2020.